Clinical Trials
79 trialsStem Cell Transplantation for Participants With Germline RUNX1 Associated Blood Cancers
National Institutes of Health Clinical Center (CC)
PCI-32765 for Special Cases of Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
National Institutes of Health Clinical Center (CC)
Cladribine With Simultaneous or Delayed Rituximab to Treat Hairy Cell Leukemia
National Institutes of Health Clinical Center (CC)
A Trial of the Safety and Immunogenicity of the COVID-19 Vaccine (mRNA-1273) in Participants With Hematologic Malignancies and Various Regimens of Immunosuppression, and in Participants With Solid Tumors on PD1/PDL1 Inhibitor Therapy
National Institutes of Health Clinical Center (CC)
Alemtuzumab (Campath) to Treat T-Large Granular Lymphocyte Leukemia
National Institutes of Health Clinical Center (CC)
Modified Stem Cell Transplant Procedure to Treat Patients With Blood and Immune System Cancers
National Institutes of Health Clinical Center (CC)
Methods to Enhance the Safety and Effectiveness of Stem Cell Transplants
National Institutes of Health Clinical Center (CC)
Immunosuppressive Preparation Followed by Blood Cell Transplant for the Treatment of Blood Cancers in Older Adults
National Institutes of Health Clinical Center (CC)
Stem Cell Transplantation and T-Cell Add-Back to Treat Bone Marrow Malignances
National Institutes of Health Clinical Center (CC)
Donor Stem Cell Transplant With No or Low-Intensity Chemotherapy Using Sirolimus and Treated Immune Cells to Treat Blood and Lymph Cancers
National Institutes of Health Clinical Center (CC)
Providing Access to Cord Blood Units for Transplants
National Institutes of Health Clinical Center (CC)
Stem Cell Transplantation for Patients With Cancers of the Blood
National Institutes of Health Clinical Center (CC)
Anti-Tac(Fv)-PE38 (LMB-2) to Treat Chronic Lymphocytic Leukemia
National Institutes of Health Clinical Center (CC)
Imatinib (Gleevec(Registered Trademark)) to Treat Chronic Myelomonocytic Leukemia and Atypical Chronic Myelogenous Leukemia
National Institutes of Health Clinical Center (CC)
Selective T-Cell Depletion to Reduce GVHD (Patients) Receiving Stem Cell Tx to Treat Leukemia, Lymphoma or MDS
National Institutes of Health Clinical Center (CC)
Cord Blood Stem Cell Transplantation Study (COBLT)
National Heart, Lung, and Blood Institute (NHLBI)
Retreatment Protocol for BL22 Immunotherapy in Relapsed or Refractory Hairy Cell Leukemia
National Institutes of Health Clinical Center (CC)
Stem Cell Transplantation and T-Cell Add-Back to Treat Bone Marrow Malignancies
National Institutes of Health Clinical Center (CC)
Rituximab in Treating Young Patients Who Are Receiving Chemotherapy for B-Cell Non-Hodgkin's Lymphoma or B-Cell Acute Lymphoblastic Leukemia
National Cancer Institute (NCI)
Effect of Cyclosporine Therapy on Gene Expression in Patients With Large Granular Lymphocyte Leukemia
National Institutes of Health Clinical Center (CC)
Bryostatin 1 and Rituximab in Treating Patients With B-Cell Non-Hodgkin's Lymphoma or Chronic Lymphocytic Leukemia
National Cancer Institute (NCI)
Phenylbutyrate, Dexamethasone, and Sargramostim in Treating Patients With Refractory or Relapsed Acute Myeloid Leukemia
National Cancer Institute (NCI)
Wilm's Tumor 1 (WT1) Peptide Vaccine for High Risk Hematologic Malignancy
National Institutes of Health Clinical Center (CC)
Umbilical Cord Blood for Stem Cell Transplantation in Treating Young Patients With Malignant or Nonmalignant Diseases
National Cancer Institute (NCI)
VNP40101M Followed by Cytarabine in Treating Older Patients With Acute Myeloid Leukemia
National Cancer Institute (NCI)
Combination Chemotherapy in Treating Adult Patients With Newly Diagnosed Acute Lymphoblastic Leukemia
National Cancer Institute (NCI)
Valproic Acid in Treating Patients With Previously Treated Non-Hodgkin Lymphoma, Hodgkin Lymphoma, or Chronic Lymphocytic Leukemia
National Cancer Institute (NCI)
Aminopterin in Treating Patients With Refractory Leukemia
National Cancer Institute (NCI)
Combination Chemotherapy Followed by Donor Bone Marrow Transplant or Peripheral Stem Cell Transplant in Treating Patients With Hematologic Cancer or Genetic Disorders
National Cancer Institute (NCI)
Oblimersen and Gemtuzumab Ozogamicin in Treating Older Patients With Relapsed Acute Myeloid Leukemia
National Cancer Institute (NCI)
Cyclosporine and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia
National Cancer Institute (NCI)
Monoclonal Antibody in Treating Patients With Acute Myelogenous Leukemia
National Cancer Institute (NCI)
Combination Chemotherapy in Treating Patients With Burkitt's Lymphoma or Burkitt's Leukemia
National Cancer Institute (NCI)
Umbilical Cord Blood and Placental Blood Transplantation in Treating Patients With Hematologic Cancer or Aplastic Anemia
National Cancer Institute (NCI)
Denileukin Diftitox in Treating Patients With Non-Hodgkin's Lymphoma
National Cancer Institute (NCI)
Silymarin (Milk Thistle Extract) in Treating Patients With Acute Lymphoblastic Leukemia Who Are Receiving Chemotherapy
National Cancer Institute (NCI)
PHA-739358 in Treating Patients With Chronic Myelogenous Leukemia That Relapsed After Imatinib Mesylate or c-ABL Therapy
National Cancer Institute (NCI)
Combination Chemotherapy in Treating Patients With Myelodysplastic Syndrome
National Cancer Institute (NCI)
Arsenic Trioxide in Treating Patients With Recurrent or Refractory Acute Leukemia, Chronic Myeloide Leukemia, Myelodysplasia, Lymphoma, or Myeloma
National Cancer Institute (NCI)
Alemtuzumab in Treating Patients With Advanced Chronic Lymphocytic Leukemia That Did Not Respond to Previous Fludarabine
National Cancer Institute (NCI)
Light-Emitting Diode Therapy in Preventing Mucositis in Children Receiving Chemotherapy With or Without Radiation Therapy Before Bone Marrow Transplantation
National Cancer Institute (NCI)
Combination Chemotherapy in Treating Adults With Acute Lymphocytic Leukemia
National Cancer Institute (NCI)
Azacitidine in Treating Patients With Chronic Myelomonocytic Leukemia
National Cancer Institute (NCI)
Alemtuzumab in Treating Patients With B-Cell Chronic Lymphocytic Leukemia in Partial Remission or Complete Remission
National Cancer Institute (NCI)
Combination Chemotherapy in Treating Patients With Relapsed or Refractory Acute Lymphocytic Leukemia
National Cancer Institute (NCI)
Fludarabine Combined With Either Alemtuzumab or Rituximab in Treating Patients With Refractory or Relapsed B-Cell Chronic Lymphocytic Leukemia
National Cancer Institute (NCI)
Combination Chemotherapy With or Without Rituximab in Treating Patients With Previously Treated Chronic Lymphocytic Leukemia
National Cancer Institute (NCI)
506U78 in Treating Patients With Chronic Lymphocytic Leukemia That Has Not Responded to Fludarabine or Alkylating Agents
National Cancer Institute (NCI)
VNP40101M in Treating Patients With Acute Myelogenous Leukemia or High-Risk Myelodysplasia
National Cancer Institute (NCI)
Combination Chemotherapy Followed by Peripheral Stem Cell Transplantation in Treating Children With Relapsed Acute Lymphocytic Leukemia
National Cancer Institute (NCI)